25 September 2023 in Acta medica Eurasica
The basis of modern strategies for the treatment of oncological diseases is the use of pharmaceutical products. A high frequency of refractoriness and formation of tumor cells' resistance to anti-EGFR drugs dictates the need to develop new active inhibitors of this intracellular kinase. The aim of this work was to study the antitumor effect of a new compound – a derivative of 9-Dihydroacridone on in vitro models of EGFR-expressing tumor cells. Material and methods. The compound of 9-aminium-3,3-dimethyl-3,4-dihydroacridine-1(2H)-one L-2-hydroxy-butandiovate (laboratory cipher of the developer institution LHT-17-19) was studied. Three cultures of human stomach cancer were used for the study. The analysis of tumor cell growth suppression was performed in a test with 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide, intracellular identification of the phosphorylated form of receptor tyrosine kinase – by Western blotting. Study results. The compound of 9-dihydroacridone dose-dependently suppresses the growth of EGFR-expressing tumor cells of human gastric cancer. Hs746T culture cells have the greatest sensitivity to the compound, MKN1 has the least. The antitumor activity of the substance is based on the ability to reduce the intracellular pool of the activated form of receptor tyrosine kinase EGFR. Conclusions. The obtained results allow enable to consider the compound LHT-17-19 as a promising compound for the subsequent preclinical study of its antitumor properties in animal systems.
30 September 2023 in Bulletin "Biomedicine and sociology"
30 September 2025 in “Educational bulletin “Consciousness”
The study involved a newovel compound, a benzoxazinone derivative Rog014. QSAR analysis was performed using the PASSonline software. The ADME methodology was used to predict pharmacokinetic parameters. Screening for antitumor activity of the compound included in the A549 tumor culture (human non-small cell lung adenocarcinoma); non-tumor human fetal lung fibroblasts MRC-5 were used for the primary safety assessment of the compound. As a result of bioinformatics prediction of biological activity of benzoxazine-2-thione compound Rog014, biological targets and types of action were established, which determine the possibility of implementing substances with antitumor activity. According to its physicochemical properties, the limiting substance has moderate lipophilicity, can be absorbed from the gastrointestinal tract, is able to penetrate the blood-brain barrier and, for determining the characteristics, can be considered as a candidate for drugs. When incubating A549 cell culture with benzoxazine-2-thione compound Rog014, IC50 was measured at 4.1 × 10-5 M; while incubation of human fibroblast culture during the study does not lead to an additional cellular side. Compound Rog014 can be considered as a candidate for an antitumor drug.